靶向PPARγ的口腔癌治疗及基因组学分析技术的附加效用
本前瞻性体外研究用吡格列酮处理口腔癌细胞,经微阵列和通路分析发现约需35个样本才能为未来研究提供足够效能,吡格列酮显著影响iCOSL和2型糖尿病通路,提示炎症与糖尿病通路或可提供假说驱动的药效学参数。
要点
- 约35个样本可为未来研究提供足够效能。
- 吡格列酮显著影响iCOSL和2型糖尿病通路。
- 全基因组分析可用于探索差异通路调节并快速生成假说。
核心结论
- 全基因组分析可用于探索差异通路调节并快速生成假说。
- 炎症和2型糖尿病通路均被显著改变,或可为未来使用噻唑烷二酮类的体外或体内研究提供独特的假说驱动药效学参数。
- 这些技术可应用于耳鼻咽喉科多种假说生成研究场景的微阵列或其他高通量数据(如中耳蛋白质组学、鼻窦微生物组研究)。
研究设计与样本
- 前瞻性体外研究,用微阵列技术、OCPlus(Bioconductor开源软件)和Ingenuity通路分析(Qiagen,美国加利福尼亚州雷德伍德城)在全基因组水平分析肿瘤细胞与吡格列酮处理肿瘤细胞的差异基因表达。
主要发现
- 约35个样本可为未来研究提供足够效能。
- 吡格列酮显著影响可诱导T细胞共刺激配体(iCOSL)和2型糖尿病通路,作为推测的抗癌机制。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Peroxisome proliferator-activated receptor γ (PPARγ) agonists have been shown to have anti-proliferative, anti-angiogenic, and proapoptotic effects, leading to interest in their use as cancer therapeutics. Pioglitazone, a U.S. Food and Drug Administration-approved type II diabetes medication and PPARγ agonist, may have a role in adjuvant head-and-neck squamous cell carcinoma treatment or prevention. Therefore, the purpose of this study was: 1) to treat oral cavity cancer cells with the PPARγ activator, pioglitazone, to analyze gene expression changes; and 2) to compare those changes with our preexisting genomic data for development of hypothesis-driven additional basic and clinical studies. STUDY DESIGN: Prospective in vitro. METHODS: We utilized microarray technology, as well as OCPlus (Bioconductor open source software) and Ingenuity Pathway Analysis (Qiagen, Redwood City, CA), to analyze differential gene expression in tumor and pioglitazone-treated tumor cells on a genome-wide level to demonstrate the feasibility of such an approach and determine appropriate sample size for future investigations. RESULTS: We found that approximately 35 samples are required to adequately power future studies. We next discovered that pioglitazone significantly affects Inducible T-Cell Costimulator (iCOS)-Ligand for the T-cell-specific cell surface receptor ICOS (iCOSL) and type II diabetes mellitus pathways as a putative anti-cancer mechanism. CONCLUSION: Genome-wide analysis is possible for the exploration of differential pathway modulation and rapid hypothesis generation. Both inflammation and type II diabetes pathways were significantly altered and therefore might provide unique hypothesis-driven pharmacodynamic parameters for future in vitro or in vivo studies utilizing thiazolidinediones. These techniques could be applied to microarray or other high throughput data from a variety of hypothesis-generating research scenarios in otolaryngology (e.g., middle ear proteomics, sinus microbiome studies). LEVEL OF EVIDENCE: NA. Laryngoscope, 127:E124-E131, 2017.
引用
- Handley N, Eide J, Taylor R, et al. PPARγ targeted oral cancer treatment and additional utility of genomics analytic techniques. Laryngoscope. 2016. PMID: 27896820. doi:10.1002/lary.26423
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。